<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224899</url>
  </required_header>
  <id_info>
    <org_study_id>SymBlock Trial</org_study_id>
    <nct_id>NCT01224899</nct_id>
  </id_info>
  <brief_title>Surgical Sympathetic Blockade in Heart Failure</brief_title>
  <acronym>SymBlock</acronym>
  <official_title>Left Cervico-Thoracic Sympathetic Blockade by Clipping in Systolic Heart Failure: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators sought to evaluate the feasibility and safety of surgical sympathetic&#xD;
      blockade in systolic heart failure patients and secondary to assess its cardiovascular&#xD;
      consequences.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative mortality and morbidity</measure>
    <time_frame>30 days after operation</time_frame>
    <description>Study interruption criteria:&#xD;
death attributable to surgical procedure;&#xD;
cardiogenic shock attributable to surgical procedure;&#xD;
worsening of heart failure symptoms attributable to surgical procedure;&#xD;
Horner's syndrome&#xD;
hypotension or bradiarrhythmia attributable to surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular effects</measure>
    <time_frame>6 months</time_frame>
    <description>left ventricle ejection fraction (echo and gated blood pool)&#xD;
end left ventricle diastolic diameter&#xD;
mean heart rate&#xD;
heart rate variability&#xD;
New York Heart Association functional class&#xD;
Minesotta Living with Heart Failure Questionnaire Score&#xD;
peak oxygen consumption&#xD;
walked distance in 6 minute walking test&#xD;
BNP&#xD;
123-I-Metaiodobenzylguanidine (late heart/mediastinum ratio)&#xD;
sympathetic peripheral nerve activity (microneurography)&#xD;
baroreflex parameters (low and high frequency)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Beta-blockers Intolerance</condition>
  <condition>Beta-blockers Resistance</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Left cervico-thoracic sympathetic blockade</intervention_name>
    <description>Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic heart failure (at least 1 month of symptoms onset)&#xD;
&#xD;
          -  NYHA functional class II or III&#xD;
&#xD;
          -  LV ejection fraction 40% or lower&#xD;
&#xD;
          -  resting heart rate higher than 65 bpm&#xD;
&#xD;
          -  either maximum beta-blocker therapy according to guidelines or no beta-blocker use for&#xD;
             intolerance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NYHA functional class I or IV&#xD;
&#xD;
          -  cardiogenic shock&#xD;
&#xD;
          -  resting heart rate ≤ 65 bpm&#xD;
&#xD;
          -  systolic blood pressure &lt; 90 mmHg&#xD;
&#xD;
          -  sustained ventricular tachycardia&#xD;
&#xD;
          -  eligibility to other surgical procedures&#xD;
&#xD;
          -  procedure-limiting comorbidity&#xD;
&#xD;
          -  presence of ICD or pacemaker&#xD;
&#xD;
          -  valvar, chagasic or congenital cardiomyopathy&#xD;
&#xD;
          -  age &gt; 70 years&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  contra-indication to videothoracoscopy&#xD;
&#xD;
          -  decompensated thyroid disease&#xD;
&#xD;
          -  atrial fibrillation or flutter&#xD;
&#xD;
          -  active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edimar A Bocchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute (InCor) HC FMUSP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paulo M Pego-Fernandes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute (InCor) HC FMUSP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Paulo Manuel Pego Fernandes</name_title>
    <organization>Heart Institute (InCor) HC FMUSP</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <keyword>Sympathectomy</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Ventricular Dysfunction, Left</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

